CVS CVS Health
Intrinsic value$9.94
Price (at call)$92.92
Margin of safety
-89.3%
vs market (rating basis)
-49.0%
Model unavailable; showing baseline valuation.
⚠ LLM error: empty response; using baseline
The story
Value drivers
| Revenue growth (Y1) | 7.6% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 2.1% |
| Years to target margin | 5 |
| Sales-to-capital | 2.97 |
| Beta | 0.60 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 7.5% |
| Terminal WACC | 8.7% |
Valuation bridge
| PV of explicit FCFF | -2.38B |
| PV of terminal value | 71.39B |
| Equity value | 12.72B |
| ÷ shares → per share | $9.94 |
News
score · 8 articles
- Can a $68 Billion Payout Save UNH Stock?
- Mark Cuban Backs Plan to Break Up Big Medicine
- How CVS' Pharmacy & Consumer Wellness Is Positioned for H2 2026
- Which Turnaround Is Better for Retirees: CVS or INTC?
- Should CVS Health’s (CVS) New Director and Youth Soccer Push Reshape Its Investment Story?
- 2 Stocks That Could Capitalize on the GLP-1 Boom
- 3 Reasons to Sell CVS and 1 Stock to Buy Instead
- Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 446.76B | 7.6% | 2.1% | 7.74B | 10.67B | -2.93B | -2.72B |
| 2 | 478.80B | 7.2% | 2.1% | 8.29B | 10.79B | -2.50B | -2.16B |
| 3 | 510.95B | 6.7% | 2.1% | 8.85B | 10.82B | -1.97B | -1.59B |
| 4 | 542.90B | 6.3% | 2.1% | 9.41B | 10.76B | -1.36B | -1.01B |
| 5 | 574.36B | 5.8% | 2.1% | 9.95B | 10.59B | -644.44M | -448.77M |
| 6 | 605.01B | 5.3% | 2.1% | 10.48B | 10.32B | 160.36M | 103.88M |
| 7 | 634.52B | 4.9% | 2.1% | 10.99B | 9.94B | 1.06B | 636.29M |
| 8 | 662.55B | 4.4% | 2.1% | 11.48B | 9.44B | 2.04B | 1.14B |
| 9 | 688.78B | 4.0% | 2.1% | 11.93B | 8.83B | 3.10B | 1.62B |
| 10 | 712.89B | 3.5% | 2.1% | 12.35B | 8.12B | 4.23B | 2.05B |
⚠ Extreme gap to market price — large, heavily-covered stocks are rarely mispriced this much; the gap likely embeds disruption, decline, or balance-sheet risk the model underweights. Treat as a flag to investigate, not a verdict.